SLEEP 2022, the 36th Annual Meeting of the Associated Professional Sleep Societies (APSS); June 4–8, 2022; Charlotte, NC

Preclinical Pharmacology of Solriamfetol: Potential Mechanisms for Wake Promotion

Hema Gursahani, PhD[1]; Thierry Jolas, PhD[2]; Maryse Martin[2]; Sandrine Cotier[2]; Sandrine Hughes[3]; Wayne Macfadden, MD[1]

[1]Jazz Pharmaceuticals, Palo Alto, CA, USA; [2]Eurofins Cerep, Celle-Lévescault, France; [3]E-Phy-Science, Biot, France

Introduction

- Solriamfetol is a wake-promoting agent (WPA) approved for the treatment of excessive daytime sleepiness associated with narcolepsy (75–150 mg/day) and obstructive sleep apnea (OSA; 37.5–150 mg/day) in the US and EU[1,2]
- The wake-promoting mechanism of solriamfetol may result from dopamine and norepinephrine reuptake inhibition (DNRI)[1,2]
  - While DNRI activity has been established for solriamfetol, its additional molecular targets are not fully characterized[1,2]

Objective

- To understand the molecular targets and effects of solriamfetol *in vitro* and *in vivo* in the context of other WPAs and stimulants

Methods

- *In vitro* binding and functional studies were conducted in a panel of cell lines or membrane preparations expressing transmembrane receptors and monoamine transporters including human dopamine and norepinephrine transporters (hDAT, hNET, respectively), human trace amine-associated receptor 1 (hTAAR1), and serotonin 1A receptor (5-HT$_{1A}$) to measure the activity of solriamfetol and comparator WPAs and DNRIs
  - Data for stimulants (eg, amphetamine, methamphetamine) were obtained from published literature
- The firing frequency of ventral tegmental area (VTA) dopaminergic neurons (n=4–8 cells/experiment) in acute slice preparations was recorded using electrophysiology and analyzed
  - Brain slices (250 µm thickness) containing VTA from male C57Bl6/J mice were prepared using standard procedures
  - Slices were perfused with artificial cerebrospinal fluid (aCSF) and spontaneous action potentials were recorded from dopaminergic neurons in current clamp conditions using Axopatch700B and pClamp10 (Axon Instruments)[3]
- Open field locomotor activity was assessed using an automated Omnitech Digiscan (AccuScan Instruments, Columbus, OH)
  - Wild type and DAT$^{-/-}$ mice (n=10/genotype/treatment group) received subcutaneous injections of vehicle or amphetamine (2 mg/kg) followed by solriamfetol (10, 30, or 100 mg/kg); total distance traveled (cm traveled in 90 minutes) was recorded

Results

Figure 1. Solriamfetol is a DNRI that activates hTAAR1 and 5-HT$_{1A}$ *in vitro* at clinically relevant plasma concentrations



5-HT$_{1A}$, serotonin 1A receptor; DNRI, dopamine and norepinephrine reuptake inhibitor; hDAT, human dopamine transporter; hNET, human norepinephrine transporter; hTAAR1, human trace amine-associated receptor 1.

References: 1. Sunosi™ (solriamfetol) tablets Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc; 2021. **2.** Sunosi™ (solriamfetol) tablets Summary of Product Characteristics. Dublin, Ireland: Jazz Pharmaceuticals Ireland Ltd; 2020. **3.** Revel FG, et al. *Proc Natl Acad Sci U S A.* 2011;108(20):8485-90. **4.** Eshleman AJ, et al. *J Pharmacol Exp Ther.* 1999;289(2):877-85. **5.** Simmler LD, et al. *J Pharmacol Exp Ther.* 2016;357(1):134-44. **6.** Schwartz MD, et al. *Neuropsychopharmacol.* 2017;42:1305-14. **7.** Schwartz MD, et al. Front Pharmacol. 2018 Feb 2;9:35.

Support and Acknowledgments: This study was supported by Jazz Pharmaceuticals. At the time that the study was conducted, Jazz Pharmaceuticals had worldwide development, manufacturing, and commercialization rights to solriamfetol, excluding certain jurisdictions in Asia. Jazz Pharmaceuticals completed the divestiture of Sunosi® (solriamfetol) in the US to Axsome Therapeutics, Inc. on May 9, 2022. SK Biopharmaceuticals, the discoverer of the compound (also known as SKL-N05), maintains rights in 12 Asian markets, including Korea, China, and Japan. Under the direction of the authors, Benjamin Hiller of Peloton Advantage, LLC, an OPEN Health company, provided medical writing and editorial support for this poster, which was funded by Jazz Pharmaceuticals.

Disclosures: H Gursahani and **W Macfadden** are employees of Jazz Pharmaceuticals who, in the course of their employment, have received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals. **T Jolas, S Cotier, M Martin,** and **S Hughes** have no conflicts to disclose.

Table 1. TAAR1 and 5-HT$_{1A}$ functional activities differentiate solriamfetol from other WPAs

Drug	hDAT IC$_{50}$ µM	hNET IC$_{50}$ µM	hTAAR1 EC$_{50}$ µM (Emax)	5-HT$_{1A}$ IC$_{50}$ µM
WPA or hDAT/hNET inhibitor				
Solriamfetol	3.21	14.4	10–16 (100%)	25
Modafinil	2.8	>100	No dose response[a]	Unknown
Bupropion	0.26	2.79	No dose response[a]	No functional activity
Stimulants				
(+) Amphetamine[b]	0.041	0.023	2.8 (91%)	Unknown
(+) Methamphetamine[b]	0.082	0.0013	5.3 (70%)	Unknown

5-HT$_{1A}$, serotonin 1A receptor; EC$_{50}$, half maximal effective concentration; Emax, maximal effect; hDAT, human dopamine transporter; hNET, human norepinephrine transporter; hTAAR1, human trace amine-associated receptor 1; IC$_{50}$, half maximal inhibitory concentration; WPA, wake-promoting agent.
[a]Data based on current studies and confirmed by published literature.[4] [b]Data from published literature.[4,5]

- Solriamfetol and stimulants had TAAR1 activity while modafinil did not
- Solriamfetol had 5-HT$_{1A}$ activity at lower potency
- No additional targets were identified for solriamfetol in a binding assay panel

Figure 2. Solriamfetol inhibited firing frequency of VTA neurons in a D2-sensitive manner

a) Solriamfetol inhibited firing by VTA neurons in a dose-dependent manner, similar to TAAR1 agonist RO5256390



b) Reduction in firing frequency by solriamfetol or TAAR1 agonist RO5256390 was antagonized by pre-treatment with the D2 receptor antagonist sulpiride



aCSF, artificial cerebrospinal fluid; TAAR1, trace amine-associated receptor 1; VTA, ventral tegmental area.

Figure 3. Solriamfetol inhibited hyperlocomotion in DAT$^{-/-}$ mice

a) Solriamfetol did not increase locomotor activity in wild type mice, unlike a stimulant

b) Solriamfetol reduced hyperlocomotion in DAT$^{-/-}$ mice, similar to a stimulant

c) RO5166017, an established TAAR1 agonist, reduced hyperlocomotion in DAT$^{-/-}$ mice[3]



Amph, amphetamine; DAT, dopamine transporter. *P<0.05 vs vehicle; **P<0.01 vs vehicle.

Conclusions

- Solriamfetol activates hTAAR1, a recently recognized component of the endogenous wake-promoting system,[6-7] *in vitro* at potencies that are within the clinically relevant plasma concentration range and overlap with observed DAT/NET inhibitory potencies
  - No hTAAR1 activity was observed for the WPA modafinil or the DNRI bupropion
- Solriamfetol shows agonist activity at the TAAR1 receptor and a lower agonist potency at 5-HT$_{1A}$
  - This activity, in addition to its established activity as a DNRI, may contribute to the wake-promoting effects of solriamfetol[1,2]
- Similar to known TAAR1 agonists, solriamfetol reduced the firing frequency of mouse VTA dopamine neurons in a D2-sensitive manner
- Unlike amphetamine, solriamfetol did not promote hyperlocomotion in naive mice; hyperlocomotion in DAT$^{-/-}$ mice was dose-dependently inhibited by solriamfetol, similar to amphetamine